Overview

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Status:
RECRUITING

Trial end date:
2026-08-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based chemotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

Jiangxi Provincial Cancer Hospital

Treatments:

Capecitabine
nimotuzumab